Integra LifeSciences (NASDAQ:IART) Updates Q3 2026 Earnings Guidance

Integra LifeSciences (NASDAQ:IART – Get Free Report) issued an update on its third quarter 2026 earnings guidance on Wednesday. The company provided EPS guidance of 0.530-0.610 for the period, compared to the consensus estimate of 0.560. The company issued revenue guidance of $410.0 million-$425.0 million, compared to the consensus revenue estimate of $417.3 million. Integra LifeSciences also updated its FY 2026 guidance to 2.400-2.500 EPS.

Integra LifeSciences Stock Performance

IART opened at $17.10 on Friday. The business’s 50-day simple moving average is $17.67 and its 200 day simple moving average is $13.45. Integra LifeSciences has a 52-week low of $8.70 and a 52-week high of $20.49. The company has a debt-to-equity ratio of 1.75, a quick ratio of 1.95 and a current ratio of 3.38. The firm has a market capitalization of $1.33 billion, a PE ratio of -189.95, a PEG ratio of 1.14 and a beta of 1.22.

Get Integra LifeSciences alerts:

Integra LifeSciences (NASDAQ:IART – Get Free Report) last posted its quarterly earnings results on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.08. Integra LifeSciences had a positive return on equity of 18.31% and a negative net margin of 0.44%.The firm had revenue of $418.76 million for the quarter, compared to analyst estimates of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. As a group, sell-side analysts expect that Integra LifeSciences will post 2.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IART has been the subject of a number of analyst reports. BMO Capital Markets assumed coverage on shares of Integra LifeSciences in a research report on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 price objective for the company. Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a report on Thursday, June 18th. Wells Fargo & Company raised their target price on shares of Integra LifeSciences from $15.00 to $18.00 and gave the company an “equal weight” rating in a research note on Thursday. Truist Financial lifted their price target on Integra LifeSciences from $14.00 to $19.00 and gave the stock a “hold” rating in a report on Thursday, July 16th. Finally, Weiss Ratings raised Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 13th. One research analyst has rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Reduce” and a consensus price target of $18.86.

Check Out Our Latest Stock Analysis on Integra LifeSciences

Hedge Funds Weigh In On Integra LifeSciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. Envestnet Asset Management Inc. acquired a new stake in shares of Integra LifeSciences in the 3rd quarter valued at $190,000. Corient Private Wealth LLC acquired a new stake in Integra LifeSciences in the fourth quarter valued at about $189,000. Renaissance Technologies LLC bought a new position in Integra LifeSciences in the fourth quarter valued at about $183,000. FourThought Financial Partners LLC bought a new position in shares of Integra LifeSciences in the third quarter worth about $179,000. Finally, Inceptionr LLC bought a new position in Integra LifeSciences in the 3rd quarter valued at approximately $164,000. 84.78% of the stock is currently owned by institutional investors and hedge funds.

About Integra LifeSciences

(Get Free Report)

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.

Featured Stories

• Five stocks we like better than Integra LifeSciences
• L3Harris’ Record Backlog Makes Its Stock Sell-Off Look Overdone
• Quantum Earnings Could Decide Whether the Sector’s Sell-Off Has Gone Too Far
• Microsoft Just Flipped the AI Spending Narrative Overnight
• Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.